Renal disease News and Research

RSS

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

Some diets and diet pills may cause further kidney damage in overweight adults

With 1 in 5 overweight Americans suffering from chronic kidney disease, Cleveland Clinic researchers analyzed the nutritional and lifestyle habits of overweight adults, finding that their methods included diets and diet pills that may cause further kidney damage.

22 Feb 2012

Low dose carbon monoxide therapy can prevent fetal death

Heme oxygenase-1 is essential for the growth of blood vessels in the placenta and in establishing blood flow in the umbilical cord. Too little HO-1 can lead to a restriction in the growth of the fetus and even in fetal death and miscarriage. New research published in BioMed Central's open access journal Medical Gas Research has shown that low dose carbon monoxide therapy is able to restore placental function and prevent fetal death in mice, without any detrimental effects.

19 Feb 2012

Eating fructose does not lead to an increase in blood pressure

Eating fructose over an extended period of time does not lead to an increase in blood pressure, according to researchers at St. Michael's Hospital.

13 Feb 2012

Excessive consumption of phosphate damages health

Excessive consumption of phosphate is damaging to health. Therefore, food that contains phosphate additives should be labeled, as recommended by Eberhard Ritz and coauthors in their article in the current issue of Deutsches Ärzteblatt International.

12 Feb 2012

Study reveals racial disparities in renal transplant access

A new study published in the American Journal of Transplantation reveals that racial disparities exist in both the early and late steps in access to kidney transplantation. This study is part of the February special themed issue of the journal on racial disparity.

10 Feb 2012

Study examines link between blood pressure and risk of ESRD under 'real world' conditions

An upward revision of the blood pressure numbers used to identify risk of end-stage renal disease (ESRD) might actually help doctors provide better care for their patients, said the authors of a study in patients with chronic kidney disease.

3 Feb 2012

New biomarkers can predict risk of kidney failure in patients with diabetes

Scientists at Joslin Diabetes Center have identified two novel markers that, when elevated in the blood stream, can predict accurately the risk of renal (kidney) failure in patients with Type 1 and Type 2 diabetes.

20 Jan 2012

Study examines effect of MELD score-based allocation on post-liver transplant kidney failure

Research from the University of Michigan Health System shows the risk for kidney failure among liver transplant recipients is higher following the implementation of Model of End Stage Liver Disease (MELD), a policy change in 2002 that altered how liver transplant allocation is decided.

18 Jan 2012

Many seniors with kidney disease are good candidates for transplants

Thousands more American senior citizens with kidney disease are good candidates for transplants and could get them if physicians would get past outdated medical biases and put them on transplant waiting lists, according to a new study by Johns Hopkins researchers.

13 Jan 2012

KAI commences enrollment in KAI-4169 second Phase 2 study for CKD-MBD

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease.

6 Jan 2012

Pharmalink raises SEK 35 million to further advance Nefecon and Busulipo

Pharmalink AB, today announces it has raised SEK 35 million through a rights issue of new shares to the Company's existing shareholders, including Industrifonden.

4 Jan 2012

The Academy of Nutrition and Dietetics to expand coverage of MNT

The Academy of Nutrition and Dietetics has prepared a request to submit to the Centers for Medicare and Medicaid Services (CMS) to expand coverage of medical nutrition therapy (MNT) for specific diseases, including hypertension, obesity, and cancer, as part of the CMS National Coverage Determination (NCD) Process.

19 Dec 2011

Historical context: The intersection of politics and Medicare policy

The 1920s-era charge that national health insurance was socialist eventually begat Ronald Reagan's 1961 anti-Medicare record album. A 1972 carve-out won special Medicare treatment for patients with end-stage renal disease.

16 Dec 2011

Certain measures of kidney health may predict who is likely to die prematurely

Certain measures of kidney health may predict who is likely to die prematurely, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

16 Dec 2011

Statins linked with reduced risk of death among hospitalized flu patients

The two main ways to prevent and control influenza today are annual immunization and antiviral drugs. A team of investigators has found that statins, cholesterol-lowering drugs, may offer an additional treatment to complement these approaches and reduce mortality among patients hospitalized with influenza.

14 Dec 2011

Relaxin improves poor blood flow and kidney function in a rat model of PKD

After a four-week course of the vasodilator hormone relaxin, kidney function and blood flow immediately improved in lab rats genetically altered to model polycystic kidney disease (PKD), a life-threatening genetic disorder, according to research presented on Dec. 6 at the American Society for Cell Biology Annual Meeting in Denver.

7 Dec 2011

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).

5 Dec 2011

Diaverum signs joint venture agreement with Nazer Group

November 2011: Diaverum, one of the world´s largest independent renal care providers, has signed a joint venture agreement with Nazer Group, a Saudi Arabian Holding Company with major investments in the medical sector including Bupa Arabia.

22 Nov 2011

American Access Care sold to to Fresenius Medical Care

TA Associates, a leading global growth private equity firm, today announced the sale of its portfolio company American Access Care (AAC) to Fresenius Medical Care AG & Co. KGaA.

7 Nov 2011